These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 9990606)

  • 21. Specific therapy based on the genotype and cellular mechanism in inherited cardiac arrhythmias. Long QT syndrome and Brugada syndrome.
    Shimizu W; Aiba T; Antzelevitch C
    Curr Pharm Des; 2005; 11(12):1561-72. PubMed ID: 15892662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long QT syndromes and torsade de pointes.
    Viskin S
    Lancet; 1999 Nov; 354(9190):1625-33. PubMed ID: 10560690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TU alternans, long QTU, and torsade de pointes: clinical and experimental observations.
    Habbab MA; el-Sherif N
    Pacing Clin Electrophysiol; 1992 Jun; 15(6):916-31. PubMed ID: 1376904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil.
    Aiba T; Shimizu W; Inagaki M; Noda T; Miyoshi S; Ding WG; Zankov DP; Toyoda F; Matsuura H; Horie M; Sunagawa K
    J Am Coll Cardiol; 2005 Jan; 45(2):300-7. PubMed ID: 15653031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fragmented QRS is associated with torsades de pointes in patients with acquired long QT syndrome.
    Haraoka K; Morita H; Saito Y; Toh N; Miyoshi T; Nishii N; Nagase S; Nakamura K; Kohno K; Kusano KF; Kawaguchi K; Ohe T; Ito H
    Heart Rhythm; 2010 Dec; 7(12):1808-14. PubMed ID: 20837161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
    Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
    J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes.
    Antzelevitch C
    Europace; 2007 Sep; 9 Suppl 4(Suppl 4):iv4-15. PubMed ID: 17766323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mode of onset of torsade de pointes in congenital long QT syndrome.
    Viskin S; Alla SR; Barron HV; Heller K; Saxon L; Kitzis I; Hare GF; Wong MJ; Lesh MD; Scheinman MM
    J Am Coll Cardiol; 1996 Nov; 28(5):1262-8. PubMed ID: 8890825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular biology of the long QT syndrome: impact on management.
    Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome.
    Shimizu W; Antzelevitch C
    J Am Coll Cardiol; 2000 Mar; 35(3):778-86. PubMed ID: 10716483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pause induced early afterdepolarizations in the long QT syndrome: a simulation study.
    Viswanathan PC; Rudy Y
    Cardiovasc Res; 1999 May; 42(2):530-42. PubMed ID: 10533588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Congenital and acquired long QT syndrome. Current concepts and management.
    Chiang CE
    Cardiol Rev; 2004; 12(4):222-34. PubMed ID: 15191637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3.
    Milberg P; Reinsch N; Osada N; Wasmer K; Mönnig G; Stypmann J; Breithardt G; Haverkamp W; Eckardt L
    Basic Res Cardiol; 2005 Jul; 100(4):365-71. PubMed ID: 15944809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heart rate variability in patients with congenital long QT syndrome.
    Perkiömäki JS; Zareba W; Couderc JP; Moss AJ
    Ann Noninvasive Electrocardiol; 2001 Oct; 6(4):298-304. PubMed ID: 11686910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inherited long QT syndrome: from ion channel to bedside.
    Vincent GM; Timothy K; Fox J; Zhang L
    Cardiol Rev; 1999; 7(1):44-55. PubMed ID: 10348966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Roles of Atrial Arrhythmias in Triggering Torsade de Pointes in Patients With Acquired Long QT Syndrome.
    Takasugi N; Endo S; Takasugi M; Tochibora R; Yoshida A; Watanabe T; Kawaguchi T; Yamada Y; Kanamori H; Ushikoshi H; Okura H
    Circ Arrhythm Electrophysiol; 2024 Oct; 17(10):e012675. PubMed ID: 39234741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-specific onset of arrhythmias in congenital long-QT syndrome: possible therapy implications.
    Tan HL; Bardai A; Shimizu W; Moss AJ; Schulze-Bahr E; Noda T; Wilde AA
    Circulation; 2006 Nov; 114(20):2096-103. PubMed ID: 17088455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiarrhythmic effect of antazoline in experimental models of acquired short- and long-QT-syndromes.
    Ellermann C; Sterneberg M; Kochhäuser S; Dechering DG; Fehr M; Eckardt L; Frommeyer G
    Europace; 2018 Oct; 20(10):1699-1706. PubMed ID: 29377987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiarrhythmic effects of free polyunsaturated fatty acids in an experimental model of LQT2 and LQT3 due to suppression of early afterdepolarizations and reduction of spatial and temporal dispersion of repolarization.
    Milberg P; Frommeyer G; Kleideiter A; Fischer A; Osada N; Breithardt G; Fehr M; Eckardt L
    Heart Rhythm; 2011 Sep; 8(9):1492-500. PubMed ID: 21459164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome.
    Shimizu W; Antzelevitch C
    Circulation; 1997 Sep; 96(6):2038-47. PubMed ID: 9323097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.